Company Overview - Connect Biopharma Holdings Limited is a global clinical-stage biopharmaceutical company focused on developing therapies for chronic inflammatory diseases through T cell-driven research [2] - The company aims to improve the lives of millions affected by these diseases by building a pipeline of proprietary small molecules and antibodies [2] Recent Developments - The Board of Directors granted non-qualified stock option awards to the newly-appointed CEO Barry Quart and President David Szekeres, totaling 2,658,734 and 1,772,489 ordinary shares respectively [1] - The options have an exercise price of $1.77 per share, which is the closing price on the grant date, and will vest over four years [1] Product Pipeline - The lead product candidate, rademikibart, targets interleukin-4 receptor alpha (IL-4Rα) and is in development for atopic dermatitis and asthma [2] - The second product candidate, icanbelimod, modulates S1P1 T cell receptors and is being developed for ulcerative colitis [2]
Connect Biopharma Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)